Lipostatic hypothesis

All unapproved Citizendium articles may contain errors of fact, bias, grammar etc. A version of an article is unapproved unless it is marked as citable with a dedicated green template at the top of the page, as in this version of the 'Biology' article. Citable articles are intended to be of reasonably high quality. The participants in the Citizendium project make no representations about the reliability of Citizendium articles or, generally, their suitability for any purpose. This article is currently being developed as part of an Eduzendium student project in the framework of a course entitled Appetite and Obesity at Edinburgh University. The course homepage can be found at CZ:UoE Appetite and Obesity 2011. For the course duration, the article is closed to outside editing. Of course you can always leave comments on the discussion page. The anticipated date of course completion is 01 April 2012. One month after that date at the latest, this notice shall be removed. Besides, many other Citizendium articles welcome your collaboration!

In 1953, Kennedy proposed what became known as the lipostatic hyothesis. Specifically, he postulated the existence, in the hypothalamus, of a centre that was sensitive to the concentration of metabolites in the circulation, which prevented "an overall surplus of energy intake over expenditure."

Introduction

The lipostatic hypothesis describes the feedback mechanisms between adipose tissue deposition and hypothalamic signalling that sustain 'lipostasis'. Lipostasis is achieved through the modulation and balancing of energy intake and expenditure to prevent an individual 'getting fat'. For the brain to know when there is too much adipose tissue building up, a signalling hormone is released from the adipose tissue to signal to the brain that a satiation signal must be released to stop the individual from eating. In 1994, it was discovered that this hormone released from adipose tissue, and critical in regulating the size of the body fat depot, was coded for by the ob gene and is known as leptin..

What is leptin?

Leptin is a adipocite derived hormone that circulates in the blood in proportion to whole body adipose tissue mass. In other words, except for ob-/ob- individuals, the more adipose tissue an individual contains, the greater the amount of leptin they have circulating in their blood. Leptin can cross the blood-brain barrier, and it acts on specific leptin receptors which are mainly located in the ventromedial nucleus (VMN) and arcuate nucleus (ARC) of the hypothalamus. The leptin signal transmits information about the size of body fat depots; in the ARC, it causes increased production of pro-opiomelanocortin (POMC), which is cleaved into functional products such as α-melanocyte stimulating hormoone (α-MSH), which then act on downstream secondary neurones leading to the release of satiation signals.

Leptin was discovered as a product of the ob gene and its role in regulating food intake was identified through ob/ob deficient mice. These mice could not produce leptin and therefore had no means of starting the feedback mechanism, as there was no signalling to the VMN and ARC of excess adipose tissue. Due to this, there is no anorexigenic response and the ob/ob mice keeps on eating due to a lack of satiation. Another mutation that further supported leptin's role in energy balance came from db/db mice. These mice have a mutation in the gene coding for leptin receptors and therefore, even though their adipose tissue produced leptin in abundance, the lack of leptin sensitive receptors also meant that there was no complete signal to the brain of excess adipose tissue.

Interestingly, leptin treatment of these two different mutant mice led to drastically different results. The ob/ob mice, when treated with leptin over time, lost a vast amount of weight as leptin elicits the anorexigenic response that the mouse could not provide before. The db/db mice however had no weight reduction from the introduction of leptin, as their receptors remained insensitive to the hormone.

Hypothalamic leptin signaling

Leptin receptor mediated hypothalamic signaling involves multiple pathways. The JAK2/cytosolic signal transducer and activator of transcription protein 3 (STAT3) pathway plays an important role, although the JAK2-Phosphotidylinosital 3 kinase (PI3K) pathway has also shown to be important. With respect to the JAK2/STAT3 pathway, leptin binding to the long form of the leptin receptor (Ob-Rb) initiates tyrosine phosphorylation of Ob-Rb by JAK2. Phosphorylated leptin receptor then recruits STAT3 that is activated through phosphorylation by JAK2. The activated STAT3 proteins dimerize and translocate to the nucleus where they bind DNA and initiate gene transcription. Suppresser of cytokine signaling 3 (SOCS-3) and phosphotyrosine phosphotase 1B (PTP1B) are two known negative regulators of leptin signaling following Ob-Rb activation through a mechanism of negative feedback. The JAK2/STAT3 pathway is believed to be essential for mediating leptin's effects on homeostatic energy regulation.

In the hypothalamus leptin binds to leptin receptors in the ARC and PVN which then activates the POMC/CART neurones leading to the synthesis of α-MSH which is a potent inhibitor of appetite. Experimetnal rodent models have shown that injection of α-MSH directly into the brain of these animals stroｎgly inhibits the feeding response。　As well as this leptin has shown to inhibit the NPY/AｇRP neurones which have been shown through animal models to be potent stimulators of appetite. There is also a communication system between these two sets of NPY/AｇRP and POMC/CART neurones- activation os one set of neurones inactivates the other set of neurones and vice versa.

Parabolis evidence

In the 1950s it was hypothesized that there was a message from the adipose　tissues　signalling　to　the　brain,　telling　the　brain　how　fat　you　are.　Three different　parabolis experiments (involving the surgical joining of two circulations of mice from a common single strain) were undertaken to try to prove this hypothesis. The experiments involved the surgical joining of: diet induced obese mice, ob/ob (leptin deficient) mice and db/db (mutant leptin receptors) mice.

Parabolis experiments

i)Diet induced obese mouse + normal lean mouse = weight loss in normal mouse
ii) Normal weight mouse + ob/ob obese mouse = weight loss in obese mouse
iii)Normal weight mouse + db/db obese mouse = weight loss and death in normal mouse

Results

In experiment i) the diet induced obese mouse is leptin insensitive (but has high levels of leptin in the circulation), therefore parabolis of the two mice means that the levels of leptin are increased in the circulation leading to weightloss in the normal mouse. In experiment ii) the ob/ob mouse has a single gene defect which means that it cannot synthesize leptin, therefore the parabolis of the mice means that the levels of leptin are increased in the circulation, this leptin can act on the hypothalamus of the ob/ob mouse leading to weight loss. In Experiment iii) the db/db mouse has mutant leptin receptors, but still synthesizes extremely high levels of leptin. The parabolis means that the levels of leptin in the circulation are significantly increased, the leptin acts on the hypothalamus of the normal weight mouse, leading to significant weight loss and eventual death.

Conclusion

There experiments proved the hypothesis right, showing that there is a factor in the blood which is released from adipose tissues and signals to the hypothalamus in the brain. this factor is now knows as leptin. It is the product of te ob gene and is a key regulatory metabolic hormone.

Experiment ii) shows that a single mutation in the ob gene prevents leptin synthesis, this has also been proven to be he case in humans, and in these humans leptin therapy has been shown to significantly improve obesity disease. In contast mutations in the leptin receoptor as far less well understood and thus far therapys used to treat these defects have been unsuccesful. Mutations in the leptin receptor (db/db) signal transduction pathway are much more common than mutations in leptin synthesis (ob/ob) therefore future work needs to be done to further charcterize the pathways involved in receptor signalling to ebanle the development of therapies to threat this disease.